If you read through the recent CMS-0057-F payer disclosures, one number stands out. Centene reverses 95.5% of its own prior authorization denials when providers appeal.

Read that twice. Centene denied the prior authorization. The provider appealed. Centene reversed itself 95 times out of 100.

In context, the industry average appeal overturn rate is 80.7%, which is already an extraordinary number. But Centene’s 95.5% is the highest of any major Medicare Advantage payer. And it is paired with a 12.3% denial rate, well above the 7.7% industry average.

That combination, high denials and near-universal overturn, has a clear operational implication. Almost every Centene denial is wrong. And the practices that are not systematically appealing them are leaving recoverable revenue on the table at a scale that compounds quickly.

The Math Is Not Subtle

Consider a practice that submits 200 Centene Medicare Advantage prior authorization requests per quarter. Apply the 12.3% denial rate. That is roughly 25 denials per quarter.

Of those 25 denials, the published 95.5% overturn rate says approximately 24 would be reversed if appealed. The remaining 1 might genuinely be a denial that holds up to review.

If your practice currently appeals every Centene denial, you recover 24 of those 25 cases. If you appeal half, you recover 12. If, like most practices, you appeal only about 11.5% (the industry-wide average appeal rate), you recover 3. That is the gap. Same denials, same patients, same clinical documentation. The difference is appeal volume.

Why Centene Sits Where It Does

The 95.5% overturn rate is not a sign that Centene is uniquely committed to fair review. It is a sign that Centene’s first-pass denial decisions are not holding up to clinical review. Whatever logic, automated or human, is generating the initial denial is producing decisions that get reversed when an actual clinician looks at them.

That pattern has been documented across payer-specific disclosures from KFF, the Senate Permanent Subcommittee on Investigations, and the OIG. It is one of the structural arguments behind CMS-0057-F’s requirements for specific denial reasons and faster timelines. The 95.5% number is essentially the receipts.

Building the Standing Protocol

Given the math, Centene denials should be on a default-to-appeal workflow. Standing protocols, pre-built templates, and automatic routing to your appeals team within 48 hours of denial receipt. A few elements that make this workflow run:

• Automatic identification. Centene denials should be flagged in your denial queue the moment they arrive, with a clear standing-protocol designation. Your appeals team should not have to decide whether to appeal. The decision is already made.
• Pre-built appeal letter language. Most Centene appeals do not require unique authoring. They require correct clinical documentation, the right CPT/HCPCS context, and a reference to the original PA submission. Templates handle the structural elements; clinical detail gets layered in.
• CMS-0057-F citation. If a Centene denial cites a vague reason (‘not medically necessary’ without supporting context), the new CMS-0057-F specificity requirements give you a regulatory citation to include in the appeal letter. That changes how the peer-to-peer reviewer reads it.
• 48-hour service level. Tier 1 payer appeals should be filed within 48 hours of denial receipt. The longer an appeal sits in the queue, the higher the risk of timely filing exposure on the underlying claim, and the lower the recovery rate.
• Outcome tracking. Track your own Centene appeal win rate monthly. If it drops materially below the published 95.5% benchmark, something in your appeal documentation is breaking down, and it is worth investigating immediately.

Where Clearinghouse Infrastructure Helps

Standing appeal protocols only work if denial visibility is fast and clean. A clearinghouse that surfaces denials clearly, separates them by payer, and integrates with your appeal workflow is the foundation that makes a default-to-appeal posture operationally viable. A clearinghouse that buries denial detail in PDFs, fragments responses across multiple files, or returns slow status updates makes systematic appeals expensive enough that practices fall back to selective appeal, and the recovery math collapses.

How HSC Supports This

Harris Secure Connect’s claims and ERA infrastructure surfaces denial detail as actionable items rather than buried line items. Combined with our 26 years of payer-specific edit depth (which keeps preventable conditions from becoming denials in the first place), it gives practices the foundation to actually operationalize a payer-tier appeal strategy.

If your team is currently letting Centene denials age in the queue because the appeal effort feels disproportionate to the recovery, the published data says the opposite. Reach out and we can walk through what changing that workflow looks like.

Related Resources

• KFF Medicare Advantage prior authorization analysis
• Senate Permanent Subcommittee on Investigations report on PA denials
• CMS Interoperability and Prior Authorization Final Rule

Got Centene MA volume and a default-to-not-appeal posture? Reach out and we can walk through what changing that workflow looks like for your specific volume.